Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård,...
-
Upload
antony-chandler -
Category
Documents
-
view
217 -
download
3
Transcript of Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård,...
![Page 1: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/1.jpg)
Screening for carcinogenic or chemopreventive effects of
prescription drugs
Anton Pottegård, MScPharm PhD
University of Southern Denmark
![Page 2: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/2.jpg)
![Page 3: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/3.jpg)
VKA – All cancersBenzodiazepiner – All cancers
Azathioprine – All cancers [Myasthenia]Disulfiram – MM/Breast/Prostate
[Alcoholics]Azathioprine – NMSC [Myasthenia]
Myasthenia – All cancersMetformin – Colon cancer [Diabetics]
Statins – NMSC Lithium – Upper urinary tract cancer
Statins – Renal cancerLithium – Colorectal cancer
PDEIs – Malignant melanomaTCA – Glioma
![Page 4: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/4.jpg)
RACEDRapid Assessment of
Carcinogenic Effects of Drugs
![Page 5: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/5.jpg)
![Page 6: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/6.jpg)
![Page 7: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/7.jpg)
![Page 8: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/8.jpg)
![Page 9: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/9.jpg)
RACED vol. 1
Table of contents:Valproic acid (sub. prostate)
AllopurinolAntidepressants
Antipsychotics (sub. prostate)Ibuprofen (sub. colon)
ThiazidesAce-inhibitors
ATII-antagonistsCalcium-channel-blockers (grp2)
Clopidogrel
![Page 10: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/10.jpg)
![Page 11: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/11.jpg)
![Page 12: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/12.jpg)
![Page 13: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/13.jpg)
DicloxacillinPottegård et al.
JAMA 2015 Jul 21;314(3):296-7.
Proton Pump Inhibitors
Henriksen et al.Pharmacoepidemiol Drug Saf. 2015
Sep 23.
AntidiabeticsStage et al.
J Thromb Haemost (Accepted)
![Page 14: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/14.jpg)
![Page 15: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/15.jpg)
RACED2
Anton PottegårdSøren Friis
René dePont ChristensenLaurel A. HabelJoshua J. GagneJesper Hallas
![Page 16: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/16.jpg)
Design
Multiple case-control study
![Page 17: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/17.jpg)
Outcome
All cancerSingle cancer sitesSingle cancer types
Based on ICD-O topography and morphology codes:
99 cancers and subtypes.
![Page 18: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/18.jpg)
![Page 19: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/19.jpg)
Exposures
Only drug classesOnly single substances
Both!
For each cancer, we included all drugs
that had 10 observed long-term users (defined as ≥8 prescriptions) among
the cases
![Page 20: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/20.jpg)
Analysis
Matching by gender and age… thereby adjusting for gender, age
and calendar time
Adjusting for Charlson-score and education
… as crude confounder adjustment
![Page 21: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/21.jpg)
Material
278,485 incident cancer cases
22,125 drug-cancer pairs
![Page 22: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/22.jpg)
Screening: Step 1
ORs estimated comparing long-term use (≥8 fills) to non-use.
Signals were defined as: OR <0.67 or >1.5, or95%CI >1.2 or <0.83
![Page 23: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/23.jpg)
Intermediary results
4,561 signals
![Page 24: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/24.jpg)
Screening: Step 2
Outcome specificityThe ratio of ORsignal to ORoverall outside
0.83-1.20.
Dose-response patternA significant slope on the dose-response
curve (p<0.10).
![Page 25: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/25.jpg)
Results
77.4% failed to meet dose-response criteria, 1.7% failed test for specificity,
1.4% failed both; thus leaving 1,020 signals.
159 at the second level of the ATC-system,351 at the fourth level of the ATC-system,
and 510 for single agents.
703 signals indicated an increased cancer risk,
317 indicated a chemopreventive effect.
![Page 26: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/26.jpg)
![Page 27: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/27.jpg)
![Page 28: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/28.jpg)
![Page 29: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/29.jpg)
All done?
What about issues of multiple testing?
What about legal issues?
![Page 30: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/30.jpg)
![Page 31: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/31.jpg)
![Page 32: Screening for carcinogenic or chemopreventive effects of prescription drugs Anton Pottegård, MScPharm PhD University of Southern Denmark.](https://reader035.fdocuments.us/reader035/viewer/2022070413/5697bf901a28abf838c8de56/html5/thumbnails/32.jpg)
Male pharmacoepidemiologist seeks enthusiastic partner who owns his/her own degree and
grows his/her own hypotheses. Access to cancer-data is a plus,
as is being open-minded!